<p>Sangamo Therapeutics（納斯達克代碼：SGMO - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的股票研究人員從 “持有” 評級下調至 “強烈賣出” 評級。</p>
<ul>
<li>2 只低價基因治療股票值得投機</li>
</ul>
<p>其他一些研究公司也最近對 SGMO 發表了評論。巴克萊在 11 月 7 日的研究報告中重申了 “持平” 評級，並將 Sangamo Therapeutics 的目標股價設定為 1.00 美元（低於 5.00 美元）。HC Wainwright 在 9 月 4 日的研究報告中重申了 “買入” 評級，並將 Sangamo Therapeutics 的目標股價設定為 10.00 美元。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了 Sangamo Therapeutics 的 “賣出（e+）” 評級。三位投資分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標股價為 3.83 美元。</p>
<p>獲取 <strong>Sangamo Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們關於 SGMO 的最新研究報告</strong></p>
<h2>Sangamo Therapeutics 股票表現</h2>
<p>納斯達克 SGMO 在週五開盤價為 0.44 美元。該公司的 50 日移動平均價格為 0.59 美元，200 日移動平均價格為 0.56 美元。Sangamo Therapeutics 的 52 周最低價為 0.41 美元，52 周最高價為 2.84 美元。該公司的市值為 1.4964 億美元，市盈率為-1.53，貝塔值為 1.25。</p>
<p>Sangamo Therapeutics（納斯達克代碼：SGMO - 獲取免費報告）在 11 月 6 日發佈了其季度財報。這家生物製藥公司報告季度每股收益為（0.11 美元），低於共識預期的（0.03 美元）0.08 美元。Sangamo Therapeutics 的股本回報率為-293.05%，淨利潤率為-77.48%。該公司季度收入為 58 萬美元，而分析師預期為 3440 萬美元。整體來看，股票分析師預測 Sangamo Therapeutics 在本年度將發佈-0.46 美元的每股收益。</p>
<h2>機構投資者對 Sangamo Therapeutics 的看法</h2>
<p>幾家大型投資者最近調整了對 SGMO 的持股。Golden State Equity Partners 在第二季度將其在 Sangamo Therapeutics 的持股增加了 5.4%。Golden State Equity Partners 目前擁有 391,943 股該生物製藥公司的股票，價值 212,000 美元，在此期間又購買了 20,000 股。World Investment Advisors 在第三季度將其在 Sangamo Therapeutics 的持股增加了 88.5%。World Investment Advisors 目前擁有 42,611 股該生物製藥公司的股票，價值 29,000 美元，在上個季度又購買了 20,000 股。Wealth Enhancement Advisory Services LLC 在第二季度將其在 Sangamo Therapeutics 的持股增加了 30.8%。Wealth Enhancement Advisory Services LLC 目前擁有 90,550 股該生物製藥公司的股票，價值 48,000 美元，在此期間又購買了 21,300 股。Wealth Management Associates Inc.在第三季度將其在 Sangamo Therapeutics 的持股增加了 9.1%。Wealth Management Associates Inc.目前擁有 335,800 股該生物製藥公司的股票，價值 226,000 美元，在上個季度又收購了 28,000 股。最後，Meritage Portfolio Management 在第二季度將其在 Sangamo Therapeutics 的持股增加了 37.3%。Meritage Portfolio Management 目前擁有 127,000 股該生物製藥公司的股票，價值 69,000 美元，在此期間又收購了 34,500 股。機構投資者持有該公司 56.92% 的股票。</p>
<h2>Sangamo Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Sangamo Therapeutics, Inc.是一家臨牀階段的基因治療公司，專注於將科學轉化為藥物，以改變美國患者及其家庭的生活，這些患者受到嚴重疾病的困擾。該公司的臨牀階段產品候選者包括 ST-920，一種基因治療產品候選者，目前正在進行針對 Fabry 病的 1/2 期臨牀研究；TX200，一種嵌合抗原受體工程調節性 T 細胞（CAR-Treg）治療產品候選者，目前正在進行針對 HLA-A2 不匹配腎移植中免疫介導排斥的 1/2 期臨牀研究；SB-525，一種基因治療產品候選者，目前正在進行針對中度至重度血友病 A 的 3 期臨牀試驗；BIVV003，一種鋅指核酸酶基因編輯細胞治療產品候選者，目前正在進行針對鐮狀細胞病的 1/2 期 PRECIZN-1 臨牀研究。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Sangamo Therapeutics</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>這三隻被低估的科技巨頭準備反彈嗎？</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>如果你等到下跌，Micron Technology 可能會讓你錯過機會</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>三隻悄然推動 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dNTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Sangamo Therapeutics 嗎？</h2>
<p>在你考慮 Sangamo Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Sangamo Therapeutics 並不在名單上。</p>
<p>雖然 Sangamo Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SGMO

<p>Sangamo Therapeutics（納斯達克代碼：SGMO）被 Wall Street Zen 從 “持有” 評級下調至 “強烈賣出” 評級。巴克萊將目標價設定為 1.00 美元，較之前的 5.00 美元下調，而 HC Wainwright 維持 “買入” 評級，目標價為 10.00 美元。該股票開盤價為 0.44 美元，52 周價格區間為 0.41 美元至 2.84 美元。機構投資者持有該股票的 56.92%。Sangamo 專注於基因醫學，擁有多個臨牀階段的產品候選者</p>

<p>Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Sangamo Therapeutics（納斯達克代碼：SGMO - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的股票研究人員從 “持有” 評級下調至 “強烈賣出” 評級。</p>
</div><ul>
<li>2 low-priced gene therapy stocks to speculate on</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只低價基因治療股票值得投機</li>
</ul>
</div><p>A number of other research firms have also recently commented on SGMO. Barclays reaffirmed an &#34;equal weight&#34; rating and set a $1.00 price target (down from $5.00) on shares of Sangamo Therapeutics in a research note on Friday, November 7th. HC Wainwright restated a &#34;buy&#34; rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Finally, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Sangamo Therapeutics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $3.83.</p>
<div class="lb-trans"><p>其他一些研究公司也最近對 SGMO 發表了評論。巴克萊在 11 月 7 日的研究報告中重申了 “持平” 評級，並將 Sangamo Therapeutics 的目標股價設定為 1.00 美元（低於 5.00 美元）。HC Wainwright 在 9 月 4 日的研究報告中重申了 “買入” 評級，並將 Sangamo Therapeutics 的目標股價設定為 10.00 美元。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了 Sangamo Therapeutics 的 “賣出（e+）” 評級。三位投資分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標股價為 3.83 美元。</p>
</div><p>Get <strong>Sangamo Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sangamo Therapeutics</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Research Report on SGMO</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 SGMO 的最新研究報告</strong></p>
</div><h2>Sangamo Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Sangamo Therapeutics 股票表現</h2>
</div><p>NASDAQ SGMO opened at $0.44 on Friday. The business's 50 day moving average price is $0.59 and its 200-day moving average price is $0.56. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $2.84. The company has a market cap of $149.64 million, a P/E ratio of -1.53 and a beta of 1.25.</p>
<div class="lb-trans"><p>納斯達克 SGMO 在週五開盤價為 0.44 美元。該公司的 50 日移動平均價格為 0.59 美元，200 日移動平均價格為 0.56 美元。Sangamo Therapeutics 的 52 周最低價為 0.41 美元，52 周最高價為 2.84 美元。該公司的市值為 1.4964 億美元，市盈率為-1.53，貝塔值為 1.25。</p>
</div><p>Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.08). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The firm had revenue of $0.58 million for the quarter, compared to analysts' expectations of $34.40 million. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.</p>
<div class="lb-trans"><p>Sangamo Therapeutics（納斯達克代碼：SGMO - 獲取免費報告）在 11 月 6 日發佈了其季度財報。這家生物製藥公司報告季度每股收益為（0.11 美元），低於共識預期的（0.03 美元）0.08 美元。Sangamo Therapeutics 的股本回報率為-293.05%，淨利潤率為-77.48%。該公司季度收入為 58 萬美元，而分析師預期為 3440 萬美元。整體來看，股票分析師預測 Sangamo Therapeutics 在本年度將發佈-0.46 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Sangamo Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Sangamo Therapeutics 的看法</h2>
</div><p>Several large investors have recently modified their holdings of SGMO. Golden State Equity Partners lifted its position in shares of Sangamo Therapeutics by 5.4% in the 2nd quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company's stock worth $212,000 after purchasing an additional 20,000 shares during the period. World Investment Advisors raised its stake in Sangamo Therapeutics by 88.5% in the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 20,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Sangamo Therapeutics by 30.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company's stock worth $48,000 after buying an additional 21,300 shares during the period. Wealth Management Associates Inc. boosted its position in Sangamo Therapeutics by 9.1% during the 3rd quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company's stock valued at $226,000 after acquiring an additional 28,000 shares in the last quarter. Finally, Meritage Portfolio Management increased its holdings in shares of Sangamo Therapeutics by 37.3% in the 2nd quarter. Meritage Portfolio Management now owns 127,000 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 34,500 shares during the period. Institutional investors own 56.92% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近調整了對 SGMO 的持股。Golden State Equity Partners 在第二季度將其在 Sangamo Therapeutics 的持股增加了 5.4%。Golden State Equity Partners 目前擁有 391,943 股該生物製藥公司的股票，價值 212,000 美元，在此期間又購買了 20,000 股。World Investment Advisors 在第三季度將其在 Sangamo Therapeutics 的持股增加了 88.5%。World Investment Advisors 目前擁有 42,611 股該生物製藥公司的股票，價值 29,000 美元，在上個季度又購買了 20,000 股。Wealth Enhancement Advisory Services LLC 在第二季度將其在 Sangamo Therapeutics 的持股增加了 30.8%。Wealth Enhancement Advisory Services LLC 目前擁有 90,550 股該生物製藥公司的股票，價值 48,000 美元，在此期間又購買了 21,300 股。Wealth Management Associates Inc.在第三季度將其在 Sangamo Therapeutics 的持股增加了 9.1%。Wealth Management Associates Inc.目前擁有 335,800 股該生物製藥公司的股票，價值 226,000 美元，在上個季度又收購了 28,000 股。最後，Meritage Portfolio Management 在第二季度將其在 Sangamo Therapeutics 的持股增加了 37.3%。Meritage Portfolio Management 目前擁有 127,000 股該生物製藥公司的股票，價值 69,000 美元，在此期間又收購了 34,500 股。機構投資者持有該公司 56.92% 的股票。</p>
</div><h2>Sangamo Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Sangamo Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.</p>
<div class="lb-trans"><p>Sangamo Therapeutics, Inc.是一家臨牀階段的基因治療公司，專注於將科學轉化為藥物，以改變美國患者及其家庭的生活，這些患者受到嚴重疾病的困擾。該公司的臨牀階段產品候選者包括 ST-920，一種基因治療產品候選者，目前正在進行針對 Fabry 病的 1/2 期臨牀研究；TX200，一種嵌合抗原受體工程調節性 T 細胞（CAR-Treg）治療產品候選者，目前正在進行針對 HLA-A2 不匹配腎移植中免疫介導排斥的 1/2 期臨牀研究；SB-525，一種基因治療產品候選者，目前正在進行針對中度至重度血友病 A 的 3 期臨牀試驗；BIVV003，一種鋅指核酸酶基因編輯細胞治療產品候選者，目前正在進行針對鐮狀細胞病的 1/2 期 PRECIZN-1 臨牀研究。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Sangamo Therapeutics</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Sangamo Therapeutics</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>這三隻被低估的科技巨頭準備反彈嗎？</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>如果你等到下跌，Micron Technology 可能會讓你錯過機會</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>三隻悄然推動 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dNTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sangamo Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Sangamo Therapeutics 嗎？</h2>
</div><p>Before you consider Sangamo Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Sangamo Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Sangamo Therapeutics 並不在名單上。</p>
</div><p>While Sangamo Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sangamo Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Sangamo Therapeutics（納斯達克代碼：SGMO）被 Wall Street Zen 下調至強烈賣出評級